Evidence map›Paper›PMID 41617829›Full record

ArticleScientific reports2026

Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas.

Alicja Petniak, Paulina Gil-Kulik, Julia Zarychta, Adrian Kowalczyk, Joanna Trubicka, Marta Perek-Polnik, Cezary Grochowski, Ryszard Maciejewski, Wiesława Grajkowska, Janusz Kocki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alicja PetniakDepartment of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str, Lublin, 20-080, Poland.
Paulina Gil-KulikDepartment of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str, Lublin, 20-080, Poland. pgil.poczt@vp.pl.
Julia ZarychtaStudent Scientific Society of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str, Lublin, 20-080, Poland.
Adrian KowalczykStudent Scientific Society of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str, Lublin, 20-080, Poland.
Joanna TrubickaDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Marta Perek-PolnikDepartment of Oncology, The Children's Memorial Health Institute, Warsaw, Poland.
Cezary GrochowskiInstitute of Health Sciences, The John Paul II Catholic University of Lublin, Konstantynów 1 str, Lublin, Poland.
Ryszard MaciejewskiInstitute of Health Sciences, The John Paul II Catholic University of Lublin, Konstantynów 1 str, Lublin, Poland.
Wiesława GrajkowskaDepartment of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.
Janusz KockiDepartment of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str, Lublin, 20-080, Poland.

Funding

Uniwersytet Medyczny w Lublinie DS 222Uniwersytet Medyczny w Lublinie DS 223
6 · The paper itself

Abstract

Inhibitors of apoptosis proteins (IAPs), coded by BIRC genes, are cellular checkpoints that can regulate and inhibit pro-apoptotic caspase signaling. Overexpression of BIRC genes has been associated with cancer progression, multidrug resistance, poor prognosis, and shorter survival in several types of cancer. Using quantitative real-time polymerase chain reaction, we examined the expression of IAP family genes and their regulators: NAIP, BIRC2, BIRC3, XIAP, BIRC5, BIRC6, BIRC7, CASP3, CASP9, DIABLO and XAF1. We also evaluated the impact of clinical parameters (programmed death receptor 1 [PD1] expression, oligodendrocyte transcription factor 2 [Olig2] expression, Ki-67 antigen expression, tumor protein p53 expression in tumor cells, patient survival time, and progression-free survival) on gene expression levels. The expression of BIRC3 (p = 0.049), NAIP (p = 0.008), and XAF1 (p = 0.032) was significantly higher in tumors negative for Ki67, whereas the remaining genes showed no significant correlation with Ki67 expression. In contrast, BIRC2 (r=-0.478 p < 0.05) and BIRC3 (r=-0.536 p < 0.05) expression levels were negatively correlated with overall survival. A similar negative association was observed between progression-free survival and the expression of BIRC2 (r=–0.481, p < 0.05) and BIRC3 (r=-0.540, p < 0.05). To our knowledge, this is the first study to comprehensively assess the relationship between the expression of IAP family genes and their regulators in a homogeneous group of patients diagnosed with pediatric high-grade gliomas (pHGGs). Our findings provide new insights into molecular mechanisms involved in the pathogenesis of pHGGs, however, these preliminary results require confirmation in larger and more detailed studies.

Indexed as

Baculoviral IAP Repeat-Containing 3 ProteinBrain NeoplasmsGliomaInhibitor of Apoptosis ProteinsUbiquitin-Protein LigasesAdolescentChildChild, PreschoolFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenMaleNeoplasm GradingNeuronal Apoptosis-Inhibitory ProteinPrognosisBaculoviral IAP Repeat-Containing 3 ProteinBIRC2 protein, humanBIRC3 protein, humanInhibitor of Apoptosis ProteinsKi-67 AntigenNeuronal Apoptosis-Inhibitory ProteinTumor Suppressor Protein p53Ubiquitin-Protein LigasesBIRCGFAPIAP familyKi67Olig2p53Pediatric high grade gliomaSynaptophysin

Identifiers

PMID41617829
PMCPMC12913816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.